Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

Turning Red Blood Cells into Versatile Drug Carriers

A startup aims to treat hard-to-treat diseases with genetically modified blood cells.

Using human cells to deliver drugs to the body has huge therapeutic potential, but existing methods can lead to abnormal cell growth and tumors.

Genetically engineering red blood cells to turn them into drug-delivery vehicles could open the door to a vast number of new therapies. And since mature red cells don’t carry any genetic material, they would also carry fewer safety risks than other gene and cell therapies. That’s the idea behind the technology unveiled today by Rubius, an 18-month-old company founded by Flagship Ventures in Cambridge, Massachusetts.

The image shows genetically engineered red blood cells grown in culture using Rubius’s proprietary technology.

Rubius’s first drug will be for phenylketonuria, or PKU, a devastating genetic disorder that renders people with the disease unable to digest the amino acid phenylalanine, which is found in most high-protein foods. Left untreated, PKU can lead to a variety of serious health problems including brain damage, but the only way to treat it is with an extremely restrictive diet.

The company has so far tested the PKU drug in animals and in human blood in the lab, and it aims to begin clinical testing next year. In addition to the PKU therapy, Rubius has developed over 50 different therapies based on red blood cells, says Avak Kahvejian, the company’s CEO and a partner at Flagship. He says the approach could lead to biologic therapies for a range of problems including hematologic disorders, autoimmune disorders, infectious diseases, and cancer.

The new technology draws on recent advances in the ability to genetically modify and grow human red blood cells from stem cells in culture. Using established molecular biology techniques, Rubius’s scientists can engineer progenitor cells taken from human bone marrow and grow blood cells that produce specific therapeutic proteins on their surface or inside the cell. Before they become fully mature, mammalian red blood cells eject their genetic material, so as a therapy they are easier to control and less risky than other stem cell and gene therapies, which can lead to abnormal cell growth and tumors.

Human red blood cells circulate for as long as four months, meaning they could potentially form the basis of long-term therapies. The cells can get anywhere in the body through the bloodstream and can protect the therapeutic agent from the immune system, says Kahvejian.

In the case of PKU, researchers have identified enzymes that can break down phenylalanine, “but you can’t just inject an enzyme into the bloodstream,” because the body will clear it quickly, and it could induce an immune reaction that would render future treatments with the same enzyme useless, says Harvey Lodish, a professor of biology and bioengineering at MIT and a member of the Whitehead Institute for Biomedical Research. Lodish, a scientific cofounder and member of Rubius’s board of directors, says engineering red blood cells to produce the desired enzyme “answers both problems.”

Lodish says animal tests suggest that engineered red blood cells can be a “very potent” therapy for a range of diseases. He says not-yet-published work from his lab has shown that cells modified to produce an antibody to a specific bacterial toxin render mice resistant to many times the lethal dose of that toxin.

It takes only a few weeks to grow cells that produce a new protein of interest—a process Kahvejian calls “rapid prototyping.” The company is remaining tight-lipped about what additional therapies might be in the pipeline, but Kahvejian says the potential for new drugs based on red blood cells is “only limited by your imagination.”

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.

Subscribe today
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

  • Insider Online Only {! insider.prices.online !}*

    {! insider.display.menuOptionsLabel !}

    Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.